SANTA CLARA, Calif.,
June 16, 2011 /PRNewswire/ --
NewCardio, Inc., (OTC BB: NWCI) a cardiac diagnostic technology
provider, announced today that two of its recent medical and
technical submissions have been accepted for their presentations at
the 33rd Annual International Conference of the IEEE Engineering in
Medicine and Biology Society conference.
The two papers: 'Wireless Monitoring of Reconstructed 12-Lead
ECG in Atrial Fibrillation Patients Enables Differential Diagnosis
of Recurrent Arrhythmias' and 'Algorithm for Quantitative
3-Dimensional Analysis of ECG Signals Improves Myocardial Diagnosis
Over Cardiologists in Diabetic Patients', will be presented during
the conference to be held September
1-4, in Boston, Mass.
NewCardio scientists and their academic medical collaborators
will present data from recently completed clinical studies that
highlight the diagnostic potentials of two company products,
CardioBip™ and my3KG™:
- The first of these studies showed that CardioBip accurately
captured, wirelessly transmitted, and reconstructed full 12-lead
ECG data from patients with atrial fibrillation (AF) who had
previously undergone a therapeutic catheter ablation procedure.
Such patients are at significant risk for stroke from recurrent
bouts of AF; moreover, currently available cardiac monitoring
techniques all have significant limitations for recurrent AF
detection that may be addressed by long-term CardioBip monitoring.
The NewCardio-sponsored study showed that (1) post-ablation AF
patients could conveniently monitor themselves for recurrent AF
with CardioBip for the entire duration of the study (6 months); (2)
CardioBip frequently detected AF recurrences, whether the patient
had symptoms or not; and (3) CardioBip was substantially more
sensitive and accurate that periodic sustained (12-lead 24 hours
Holter) monitoring in detecting recurrent AF.
- The second study showed that my3KG was substantially more
sensitive and accurate than the standard 12-lead electrocardiogram
in diagnosing acute heart attack (myocardial infarction, or MI) in
patients with Type II diabetes mellitus (Type II DM). This is
a significant and important advance because Type II DM is a large
and growing patient population with a high risk of MI, and a
population in which an accurate MI diagnosis is notoriously
difficult to obtain.
"This now marks the third consecutive year this prestigious
medical conference has accepted two of our papers for
presentation," said Dorin Panescu,
Ph.D., Chief Technical Officer of NewCardio and a Fellow of the
IEEE. "The acceptance of these submissions reflects the
growing recognition of the quality and innovative nature of our
science and technology, and that they meet important and previously
unmet medical needs."
The conference program will consist of plenary lectures,
symposia, workshops and invited sessions of the latest significant
findings and developments in all the major fields of biomedical
engineering. Submitted papers were peer reviewed. The NewCardio
studies will be presented in oral sessions at the IEEE meeting, and
will appear in the Conference Proceedings, which are indexed in
PubMed/MEDLINE.
About the IEEE
IEEE is the world's largest professional association dedicated
to advancing technological innovation and excellence for the
benefit of humanity. IEEE and its members inspire a global
community through IEEE's highly cited publications, conferences,
technology standards, and professional and educational activities.
IEEE's core purpose is to foster technological innovation and
excellence for the benefit of humanity.
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company
developing and marketing proprietary software platform technologies
to provide higher accuracy to, and increase the value of, the
standard 12-lead ECG. NewCardio's 3D ECG software platform
reduces the time and expense involved in assessing cardiac status
while increasing the ability to diagnose clinically significant
conditions which were previously difficult to detect.
NewCardio's software products and services significantly
improve the diagnosis and monitoring of cardiovascular disease, as
well as cardiac safety assessment of drugs under development. For
more information, visit www.newcardio.com.
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements include, but are not limited to,
statements that express our intentions, beliefs, expectations,
strategies, predictions or any other statements relating to our
future activities or other future events or conditions. These
statements are based on current expectations, estimates and
projections about our business based on currently available
information and assumptions made by management. Although we believe
that the assumptions on which the forward-looking statements
contained herein are based are reasonable, any of those assumptions
could prove to be inaccurate given the inherent uncertainties as to
the occurrence or nonoccurrence of future events. These statements
are not guarantees of future performance and involve risks and
uncertainties that are difficult to predict. Therefore, actual
outcomes and results may, and are likely to, differ materially from
what is expressed or forecasted in the forward-looking statements
due to numerous factors, including the potential risks and
uncertainties set forth in Item 1A of our Annual Report on Form
10-K for the year ended December 31,
2010 and relate to our business plan, our business strategy,
development of our proprietary technology platform and our
products, timing of such development, timing and results of
clinical trials, level and timing of FDA regulatory clearance or
review, market acceptance of our products, protection of our
intellectual property, implementation of our strategic, operating
and people initiatives, benefits to be derived from personnel and
directors, ability to commercialize our products, our assumptions
regarding cash flow from operations and cash on-hand, the amount
and timing of operating costs and capital expenditures relating to
the expansion of our business, operations and infrastructure,
implementation of marketing programs, our key agreements and
strategic alliances, our ability to obtain additional capital as,
and when, needed, and on acceptable terms and general economic
conditions specific to our industry, any of which could impact
sales, costs and expenses and/or planned strategies and timing. We
assume no obligation to, and do not currently intend to, update
these forward-looking statements.
To join our email distribution please click this link:
http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
Investor Contact:
Hyden IR
Jeff Stanlis, Partner
(602) 476-1821
jeff@haydenir.com
SOURCE NewCardio, Inc.
